Cerecor Inc. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 07, 2021 16:01 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS
January 05, 2021 07:00 ET
|
Cerecor Inc.
COVID-19 ARDS patients treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 demonstrated robust improvement in the primary endpoint (proportion of patients alive and free of...
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for the Treatment of Still’s Disease
December 22, 2020 13:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
December 16, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma
December 08, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-803 to Treat Leukocyte Adhesion Deficiency Type II
December 01, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor to Collaborate with Frontiers CDG Consortium on Pivotal Trial of CERC-801 for the Treatment of PGM1-CDG
November 17, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
November 09, 2020 16:01 ET
|
Cerecor Inc.
On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end Strengthened leadership team with the appointment of Gilla Kaplan, Ph.D., to the Board of...
Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors
October 12, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
Cerecor to Present at Upcoming Investor Conferences
September 10, 2020 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...